We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

THE BINDING SITE

Engages in the research, development, manufacture, and distribution of immunodiagnostic assays, as wel as specialized... read more Featured Products: More products

Download Mobile App




Sensitive Method Detects Free Monoclonal Light Chains in Serum

By LabMedica International staff writers
Posted on 26 Oct 2021
Neoplastic monoclonal gammopathies (NMG) consist of monoclonal gammopathy of undetermined significance (MGUS), asymptomatic or smoldering multiple myeloma (SMM) and multiple/plasma cell myeloma (MM). More...


Multiple myeloma is a malignant tumor of plasma cells and is generally associated with synthesis and secretion of monoclonal immunoglobulins by tumor cells. MM is the commonest hematologic malignancy in adults. Higher levels of serum free monoclonal light chains (SFLC) have been observed to result in shorter survival, perhaps through induction of renal damage.

Clinical Pathologists at the Medical College of Georgia at Augusta University (Atlanta, GA, USA) investigated a sensitive method for detecting free monoclonal light chains in serum that could provide a marker for residual/minimal residual disease and as an adjunct to serum protein electrophoresis to serve as a screening method for monoclonal gammopathies.

Quantification of SFLC was conducted by using kits procured from The Binding Site and assayed with an Optilite analyzer (Birmingham, UK). Rabbit polyclonal antisera to kappa and lambda free light chains were procured from SEBIA Inc. (Norcross, GA, USA). Residual clinical serum samples were assessed for monoclonal SFLC by a modified serum immunofixation protein electrophoresis (SIFE) procedure (the Modified SIFE was designated FLC-Modified SIFE). Results from this modified immunofixation electrophoresis were compared with results from commercially available MASS-FIX/MALDI assay (Mayo Clinic Laboratories, Rochester, MN, USA).

The scientists reported that monoclonal free kappa light chains could be detected to a concentration of about 1.78 mg/L and monoclonal free lambda light chains to a concentration of about 1.15 mg/L without the need for special equipment. Comparison of these thresholds with parallel results from a commercially available MASS-FIX/MALDI assay revealed the modified electrophoretic method to be more sensitive in the context of free monoclonal light chains. FLC-Modified SIFE revealed monoclonal light chains in agreement with the expected findings, given a patient's diagnosis and immunoglobulin type determined by conventional SPEP and SIFE.

The authors concluded that modified serum immunofixation electrophoresis has been shown to detect low levels of monoclonal free light chains at a sensitivity suitable for the method to be used in detecting minimal residual disease, and potentially in a screening assay for monoclonal gammopathies. The disparity in the results with commercially available MASS-FIX/MALDI assay is postulated to be due to limited repertoire of reactivity of nanobodies of camelid origin. The study was published on October 12, 2021 in the journal Practical Laboratory Medicine.

Related Links:
Medical College of Georgia at Augusta University
The Binding Site
SEBIA Inc
Mayo Clinic Laboratories



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.